Is Mounjaro covered by the HSE? — 6 vital updates for 2026.

Is Mounjaro covered by the HSE is quickly becoming one of the most consequential questions in Irish healthcare right now. What started as a straightforward “not yet” answer has, over the past year, turned into a genuinely fast-moving story involving billion-euro cost estimates, a reported price cut, and a health minister putting a real timeline on the table.

This guide walks through exactly where the Mounjaro reimbursement decision actually stands as of mid-2026, based on public statements from the HSE, the National Centre for Pharmacoeconomics (NCPE), and the Minister for Health. Official updates are published by the National Centre for Pharmacoeconomics (NCPE).

Is Mounjaro covered by the HSE — update 1: the current situation

As of mid-2026, the plain answer is no. Mounjaro is not currently reimbursed by the HSE, and is not covered by the Medical Card or the Drug Payment Scheme for weight management. Anyone accessing it today for weight loss pays privately for both the medication itself and any clinical consultation involved.

This is despite Mounjaro holding a dual EMA licence covering both type 2 diabetes and weight management, and despite manufacturer Eli Lilly having formally applied to the HSE for reimbursement across both indications — diabetes in January 2024, and weight management separately in June 2024. Both applications have been under review since, with neither yet reaching a final decision.

It’s worth understanding why this matters beyond the headline figure. Mounjaro is already reimbursed in some form for type 2 diabetes in a number of European countries, and Ireland’s own HSE covers similar GLP-1 class medications for diabetes through the Long Term Illness scheme. The genuine sticking point has consistently been the weight-management indication specifically, where the scale of potential demand — and the corresponding cost to the State — is significantly larger than for a narrower diabetes-only population.

Is Mounjaro covered by the HSE — update 2: why it was rejected initially

The NCPE’s initial assessment concluded that reimbursing Mounjaro for all eligible patients would not represent value for money at the price originally proposed. The estimated cost of adding Mounjaro to the HSE reimbursement scheme was put at up to €5.2 billion over five years — a figure large enough that consultant endocrinologist Prof Donal O’Shea reportedly warned it could strain the health budget if extended to everyone who might benefit.

NCPE Clinical Director Prof Michael Barry addressed this directly on RTÉ, noting that price reductions of 30 to 40% are not unusual in these negotiations, meaning an initially rejected drug can still become cost-effective once commercial terms improve.

Is Mounjaro covered by the HSE — update 3: the reported price cut

This is the genuinely significant recent development. Speaking on RTÉ’s This Week in June 2026, Prof Barry indicated that a substantial price reduction had since been offered, and that the NCPE now expects to find Mounjaro cost-effective, or very close to it, once formal figures are confirmed.

With this reported reduction factored in, the estimated cost to the State has fallen from the original €5.2 billion figure to a revised range of roughly €2 to €3 billion over five years — still a very large sum, but a meaningfully different starting point for the HSE Senior Leadership Team’s eventual decision.

Is Mounjaro covered by the HSE — update 4: the minister’s timeline

Health Minister Jennifer Carroll MacNeill has stated that the reimbursement application could be approved by the end of 2026 — the clearest timeline commitment given publicly so far on the is Mounjaro covered by the HSE question. This came alongside confirmation from Prof O’Shea, the HSE’s national clinical lead for obesity, that a health technology assessment (HTA) was due for publication in the weeks following.

That HTA represents the formal precursor step — evaluating the medical, social, ethical, and economic implications of covering Mounjaro — before the HSE Drugs Group makes its recommendation to the HSE Senior Leadership Team, the body that holds final decision-making authority.

Is Mounjaro covered by the HSE — update 5: likely initial eligibility

Even with an approval, universal access is very unlikely from day one. Prof O’Shea has suggested the initial criteria would probably mirror the UK’s approach — broadly, adults with a BMI over 35 alongside weight-related complications — rather than opening reimbursement to the full population who could theoretically benefit.

Under that kind of threshold, Prof O’Shea estimated as many as 80,000 people in Ireland could become eligible in an initial phase. For context, this sits against a backdrop where roughly a quarter of the Irish population lives with obesity, illustrating why a phased, criteria-based rollout is considered the realistic starting point rather than immediate universal coverage.

Prof O’Shea has also been candid about the tension this creates in practice — describing concern about the lengths people are currently going to in order to access treatments that are already established as effective and safe. This captures the core policy dilemma at the heart of the is Mounjaro covered by the HSE question: a treatment with strong clinical evidence, priced at a level the health system has so far judged difficult to sustain at full scale.

Is Mounjaro covered by the HSE — the political scrutiny building

This story has moved beyond health policy circles into direct political scrutiny. A formal parliamentary question was tabled asking the Minister for Health precisely which National Centre for Pharmacoeconomics evaluations have been completed for both tirzepatide (Mounjaro) and semaglutide (Wegovy), when each assessment began, what stage each has reached, and which month in 2026 a pricing and reimbursement decision is expected to reach the HSE Senior Leadership Team.

The level of parliamentary detail being requested — asking for exact assessment start dates and expected decision months rather than general updates — reflects how closely this issue is now being tracked by public representatives, likely driven by sustained constituent interest in a treatment that remains financially out of reach for many who could benefit from it.

Is Mounjaro covered by the HSE — update 6: Wegovy’s separate track

It’s worth being precise here: Mounjaro and Wegovy are being assessed entirely separately, despite frequently being discussed together in coverage of this story. Novo Nordisk applied for HSE reimbursement of Wegovy in March 2025, distinct from Eli Lilly’s Mounjaro applications, and each undergoes its own independent NCPE evaluation and HSE decision-making process.

This means a positive decision on Mounjaro would not automatically extend to Wegovy, or vice versa — each drug’s reimbursement status needs to be tracked and confirmed individually, even though both are frequently grouped together in general “weight loss injection” news coverage.

For current private pricing while this decision remains pending, read our guide on Mounjaro cost Ireland. Explore our Mounjaro product page, or read patient reviews.

We’ll continue monitoring this story closely and update this guide as the health technology assessment is published and the HSE Senior Leadership Team moves toward a final decision — check back here for the latest confirmed status rather than relying on older coverage elsewhere.